News & Events

In our autumn newsletter 2018 we wrote of how the NHS had reversed its previous decision and now recommends Ocrelizumab (drug name Ocrevus) for the treatment of relapsing remitting MS.

Disappointingly however, at the same time, NICE announced that Ocrevus was still too expensive for people with Primary Progressive MS (PPMS).

The good news is that the NHS struck a deal with Roche (the pharmaceutical company) and patients with PPMS are now able to access the drug. It is estimated that 10,000-15,000 people have Primary progressive MS (PPMS) in the UK, of whom around 2,700 people could be eligible for treatment with Ocrevus.

If you have Primary Progressive MS and you have started to take Ocrevus please feedback to us. We welcome all feedback about drugs and you can contribute by going on our Drugs directory as someone that can talk with other members about a drug you have experience of.

To find out more information about Ocrevus head to: www.mstrust.org.uk/a-z/ocrevus-ocrelizumab